The post Travel tips for people with MS: A comprehensive guide appeared first on MS Australia. Source: www.msaustralia.org.au
The post Helping healthcare providers support people with MS through exercise appeared first on MS Australia. Source: www.msaustralia.org.au
The post MS Nurses share knowledge and help shape future care at Auckland meeting appeared first on MS Australia. Source: www.msaustralia.org.au
The post Promising early results for a new BTK inhibitor for progressive MS appeared first on MS Australia. Source: www.msaustralia.org.au
The holidays have a way of turning up the volume on everything. The lights feel brighter, rooms feel busier, and even soft conversation seems amplified. Living with multiple sclerosis (MS) has taught me that this kind of noise isn’t just sound — it’s work. It’s…
Simultaneously measuring levels of two blood proteins — glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) — may offer a clearer way to track both disease activity and disability progression in people with multiple sclerosis (MS), according to a new long-term study. Each…
People with multiple sclerosis (MS) have a higher risk of dying by suicide than the general population, according to a meta-analysis of published studies. Nearly one-quarter of participants in the studies had thoughts about suicide (suicidal ideation). Across the studies, 0.5% of participants died by…
Tweet Roche announced in early Oct that their BTKi (Bruton’s Tyrosine Kinase inhibitor) was non-inferior to ocrelizumab (anti-B-cell) in PPMS. In a pivotal PPMS study (FENtrepid), fenebrutinib slowed disability progression at least as effectively as OCREVUS, the only approved therapy in PPMS [Ad hoc announcement…
A shopping trip goes awry I’m pleased to report that I’ve still got it! Even as I approach my middle ages, I still can pull it off. Just a few weeks ago, I was picked up by not one, but two younger guys! Here’s how…
A Phase 2 clinical trial testing PIPE-307, an experimental therapy designed to support myelin repair in people with multiple sclerosis (MS), has failed to meet its primary or secondary efficacy goals. The U.S.-based VISTA trial (NCT06083753) enrolled more than 180 adults with relapsing-remitting MS (RRMS).…